Logo image of SPRO

SPERO THERAPEUTICS INC (SPRO) Stock Fundamental Analysis

NASDAQ:SPRO - Nasdaq - US84833T1034 - Common Stock - Currency: USD

0.831  -0.01 (-0.68%)

After market: 0.83 0 (-0.12%)

Fundamental Rating

4

Overall SPRO gets a fundamental rating of 4 out of 10. We evaluated SPRO against 572 industry peers in the Biotechnology industry. SPRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SPRO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year SPRO was profitable.
SPRO had a negative operating cash flow in the past year.
In the past 5 years SPRO reported 4 times negative net income.
In the past 5 years SPRO always reported negative operating cash flow.
SPRO Yearly Net Income VS EBIT VS OCF VS FCFSPRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of 2.60%, SPRO belongs to the top of the industry, outperforming 93.61% of the companies in the same industry.
SPRO has a Return On Equity of 5.36%. This is amongst the best in the industry. SPRO outperforms 94.32% of its industry peers.
Industry RankSector Rank
ROA 2.6%
ROE 5.36%
ROIC N/A
ROA(3y)-25.72%
ROA(5y)-37.19%
ROE(3y)-47.16%
ROE(5y)-56.57%
ROIC(3y)N/A
ROIC(5y)N/A
SPRO Yearly ROA, ROE, ROICSPRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K

1.3 Margins

With an excellent Profit Margin value of 3.30%, SPRO belongs to the best of the industry, outperforming 93.96% of the companies in the same industry.
The Operating Margin and Gross Margin are not available for SPRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 3.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRO Yearly Profit, Operating, Gross MarginsSPRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

SPRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRO has been increased compared to 1 year ago.
SPRO has more shares outstanding than it did 5 years ago.
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRO Yearly Shares OutstandingSPRO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
SPRO Yearly Total Debt VS Total AssetsSPRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

SPRO has an Altman-Z score of -2.66. This is a bad value and indicates that SPRO is not financially healthy and even has some risk of bankruptcy.
SPRO's Altman-Z score of -2.66 is in line compared to the rest of the industry. SPRO outperforms 48.85% of its industry peers.
There is no outstanding debt for SPRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.66
ROIC/WACCN/A
WACC9.44%
SPRO Yearly LT Debt VS Equity VS FCFSPRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.68 indicates that SPRO has no problem at all paying its short term obligations.
With a Current ratio value of 2.68, SPRO is not doing good in the industry: 70.16% of the companies in the same industry are doing better.
SPRO has a Quick Ratio of 2.68. This indicates that SPRO is financially healthy and has no problem in meeting its short term obligations.
SPRO has a Quick ratio of 2.68. This is in the lower half of the industry: SPRO underperforms 68.03% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.68
SPRO Yearly Current Assets VS Current LiabilitesSPRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

SPRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.36%.
The Revenue has grown by 37.01% in the past year. This is a very strong growth!
SPRO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 92.07% yearly.
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)37.01%
Revenue growth 3Y123.23%
Revenue growth 5Y92.07%
Sales Q2Q%-47.12%

3.2 Future

Based on estimates for the next years, SPRO will show a decrease in Earnings Per Share. The EPS will decrease by -3.80% on average per year.
The Revenue is expected to grow by 5.20% on average over the next years.
EPS Next Y-280.46%
EPS Next 2Y-76.4%
EPS Next 3Y-44.23%
EPS Next 5Y-3.8%
Revenue Next Year-20.29%
Revenue Next 2Y-21.66%
Revenue Next 3Y-70.15%
Revenue Next 5Y5.2%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
SPRO Yearly Revenue VS EstimatesSPRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50M 100M 150M 200M
SPRO Yearly EPS VS EstimatesSPRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SPRO is valuated reasonably with a Price/Earnings ratio of 11.87.
97.51% of the companies in the same industry are more expensive than SPRO, based on the Price/Earnings ratio.
SPRO is valuated cheaply when we compare the Price/Earnings ratio to 29.63, which is the current average of the S&P500 Index.
SPRO is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 11.87
Fwd PE N/A
SPRO Price Earnings VS Forward Price EarningsSPRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRO Per share dataSPRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

SPRO's earnings are expected to decrease with -44.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-76.4%
EPS Next 3Y-44.23%

More info and screens

0

5. Dividend

5.1 Amount

SPRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPERO THERAPEUTICS INC

NASDAQ:SPRO (2/21/2025, 8:00:02 PM)

After market: 0.83 0 (-0.12%)

0.831

-0.01 (-0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners25.51%
Inst Owner Change-87.92%
Ins Owners5.2%
Ins Owner Change16.25%
Market Cap45.31M
Analysts80
Price Target5.1 (513.72%)
Short Float %0.89%
Short Ratio1.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.26%
Min EPS beat(2)13.65%
Max EPS beat(2)14.86%
EPS beat(4)3
Avg EPS beat(4)156.67%
Min EPS beat(4)-443.03%
Max EPS beat(4)1041.18%
EPS beat(8)7
Avg EPS beat(8)257.83%
EPS beat(12)8
Avg EPS beat(12)169.33%
EPS beat(16)10
Avg EPS beat(16)128.51%
Revenue beat(2)2
Avg Revenue beat(2)139.14%
Min Revenue beat(2)72.24%
Max Revenue beat(2)206.03%
Revenue beat(4)3
Avg Revenue beat(4)126.83%
Min Revenue beat(4)-57.81%
Max Revenue beat(4)286.85%
Revenue beat(8)7
Avg Revenue beat(8)116%
Revenue beat(12)8
Avg Revenue beat(12)72.28%
Revenue beat(16)10
Avg Revenue beat(16)57.72%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)13.89%
EPS NQ rev (3m)10.58%
EPS NY rev (1m)13.21%
EPS NY rev (3m)18.22%
Revenue NQ rev (1m)106.67%
Revenue NQ rev (3m)106.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)29.65%
Valuation
Industry RankSector Rank
PE 11.87
Fwd PE N/A
P/S 0.43
P/FCF N/A
P/OCF N/A
P/B 0.69
P/tB 0.69
EV/EBITDA N/A
EPS(TTM)0.07
EY8.42%
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS1.95
BVpS1.2
TBVpS1.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.6%
ROE 5.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3.3%
GM N/A
FCFM N/A
ROA(3y)-25.72%
ROA(5y)-37.19%
ROE(3y)-47.16%
ROE(5y)-56.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.68
Quick Ratio 2.68
Altman-Z -2.66
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
EPS Next Y-280.46%
EPS Next 2Y-76.4%
EPS Next 3Y-44.23%
EPS Next 5Y-3.8%
Revenue 1Y (TTM)37.01%
Revenue growth 3Y123.23%
Revenue growth 5Y92.07%
Sales Q2Q%-47.12%
Revenue Next Year-20.29%
Revenue Next 2Y-21.66%
Revenue Next 3Y-70.15%
Revenue Next 5Y5.2%
EBIT growth 1Y-152.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.96%
OCF growth 3YN/A
OCF growth 5YN/A